China's Dalian Fusheng Pharmaceutical Company Co., Ltd. Sponsors Fellowship in Geriatric Medicine through the Milstein Medical Asian American Partnership (MMAAP) Foundation

NEW YORK, April 4, 2016 /PRNewswire-USNewswire/ -- Dalian Fusheng Pharmaceutical Company Co., Ltd has contributed $85,000 to the Milstein Medical Asian American Partnership (MMAAP) Foundation to support one Fellowship Award in Geriatric Medicine. The fellowship, under the MMAAP Foundation's Irma and Paul Milstein Program for Senior Health, will provide support in 2016 to a promising investigator for one year's training in clinical or basic research in the United States at a distinguished partner institution.

Dalian Fusheng Pharmaceutical Company Co., Ltd specializes in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. Focused on innovation, it has extensive experience in producing high quality botanical extracts for dietary supplement, as well as excellent pharmaceutical and nutraceutical products.

The MMAAP Foundation was established in 2011 with a strong endorsement from China's former Ministry of Health (now the National Health and Family Planning Commission). Its mission is to improve world health by facilitating exchanges and long-term partnerships between leading medical institutions and medical talent from the United States and China, as well as greater Asia. The Foundation currently offers funding opportunities for Chinese researchers in Geriatric Medicine, Dermatology, Hematology, Reproductive Medicine and Translational Medicine in the form of fellowships and research project awards. The MMAAP Foundation plans to support other disciplines of research and make funding available to investigators from other regions of Asia in the future. For a complete listing of the MMAAP Foundation's awards, please visit www.mmaapf.org.

"We aim at exploring rich resources in Chinese Traditional Medicine to better help prevent and treat modern-day diseases," said Dr. Fu Li, the Chair of Dalian Fusheng Pharmaceutical Company Co., Ltd.

"Enhancing senior health care is a crucial task for China as well as the rest of the world," said Howard P. Milstein, Chairman of the MMAAP Foundation. I am appreciative of Dalian Fusheng Pharmaceutical Company's foresight in supporting and recognizing our mission. Such a generous contribution will not only allow us to facilitate much needed medical progress in an international setting, but also build trust and collaboration that will benefit future generations."

Dalian Fusheng Pharmaceutical Company Co., Ltd.

Fusheng Pharmaceutical Co., Ltd is specialized in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. It has extensive experience in producing high quality botanical extracts for dietary supplement, as well as the pharmaceutical and nutraceutical industries. It is the leading manufacturer of ginsenoside Rg3 in the world. As a science-driven company, we are committed to providing customers with the highest quality products and excellent service.

Milstein Medical Asian American Partnership (MMAAP) Foundation

The mission of the Milstein Medical Asian American Partnership Foundation (MMAAP Foundation) is to improve world health by developing mutually beneficial partnerships between the U.S. and China, as well as greater Asia. Working with some of the premier health organizations in the world, the MMAAP Foundation brings together and funds exchanges between top researchers, medical talent, and medical institutions.

For more than 50 years, the Milstein family has been actively involved in health-related and medical philanthropy. The MMAAP Foundation builds upon this distinguished history in five areas: Senior Healthcare, Skin Disease and Melanoma, Reproductive Biology, Blood Research, and Translational Medicine. The MMAAP Foundation works in close collaboration with other medical organizations supported by the Milstein family, including American Skin Association, the Milstein Melanoma Research Program at the Rockefeller University, the Howard and Georgeanna Jones Foundation for Reproductive Medicine, New York Blood Center, and the Program for Translational Chemical Biology at New York-Presbyterian Hospital/Weill Cornell Medical Center. The MMAAP Foundation is a 501(c)(3) non-profit organization. For more information, please visit the MMAAP Foundation's website at www.mmaapf.org.

SOURCE Milstein Medical Asian American Partnership Foundation

Related Links

http://www.mmaapf.org